Literature DB >> 9741085

A novel proline-rich protein, EspF, is secreted from enteropathogenic Escherichia coli via the type III export pathway.

B P McNamara1, M S Donnenberg.   

Abstract

Enteropathogenic Escherichia coli (EPEC) cause a characteristic attaching and effacing (A/E) lesion in intestinal epithelial cells that is associated with the expression and export of specific bacterial proteins via a type III secretion pathway. These effector proteins and components of the type III export apparatus are encoded on a pathogenicity island known as the locus of enterocyte effacement (LEE). In this study, we describe a proline-rich protein, EspF, encoded by the LEE that is secreted by the EPEC type III secretion apparatus. Whereas an espF deletion mutant does not synthesize or secrete EspF, surprisingly it retains the ability to induce host signaling events, perform A/E activities, and invade host epithelial cells. Although these results do not indicate on obvious role for EspF in the formation of A/E lesions nor in the invasion of epithelial cells, they do not preclude a role played by EspF in other aspects of EPEC pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741085     DOI: 10.1111/j.1574-6968.1998.tb13185.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  64 in total

1.  Enteropathogenic Escherichia coli mediates antiphagocytosis through the inhibition of PI 3-kinase-dependent pathways.

Authors:  J Celli; M Olivier; B B Finlay
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

2.  Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function.

Authors:  B P McNamara; A Koutsouris; C B O'Connell; J P Nougayréde; M S Donnenberg; G Hecht
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 3.  Pathogenesis and evolution of virulence in enteropathogenic and enterohemorrhagic Escherichia coli.

Authors:  M S Donnenberg; T S Whittam
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

4.  A gene from the locus of enterocyte effacement that is required for enteropathogenic Escherichia coli to increase tight-junction permeability encodes a chaperone for EspF.

Authors:  Simon J Elliott; Colin B O'Connell; Athanasia Koutsouris; Carl Brinkley; Michael S Donnenberg; Gail Hecht; James B Kaper
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 5.  Virulence of enteropathogenic Escherichia coli, a global pathogen.

Authors:  S C Clarke; R D Haigh; P P E Freestone; P H Williams
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

6.  Identification of the secretion and translocation domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter.

Authors:  Xavier Charpentier; Eric Oswald
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

7.  Transcriptome of enterohemorrhagic Escherichia coli O157 adhering to eukaryotic plasma membranes.

Authors:  Sivan Dahan; Stuart Knutton; Robert K Shaw; Valerie F Crepin; Gordon Dougan; Gad Frankel
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  The EspF effector, a bacterial pathogen's Swiss army knife.

Authors:  Ashleigh Holmes; Sabrina Mühlen; Andrew J Roe; Paul Dean
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

9.  EutR is a direct regulator of genes that contribute to metabolism and virulence in enterohemorrhagic Escherichia coli O157:H7.

Authors:  Deborah H Luzader; David E Clark; Laura A Gonyar; Melissa M Kendall
Journal:  J Bacteriol       Date:  2013-08-30       Impact factor: 3.490

10.  Interaction of enteropathogenic Escherichia coli with human intestinal mucosa: role of effector proteins in brush border remodeling and formation of attaching and effacing lesions.

Authors:  Robert K Shaw; Jennifer Cleary; Michael S Murphy; Gad Frankel; Stuart Knutton
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.